Your session is about to expire
← Back to Search
FGFR Inhibitor
KIN-3248 for Solid Tumors
Phase 1
Waitlist Available
Research Sponsored by Kinnate Biopharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Do you currently have cholangiocarcinoma (advanced intrahepatic or bile duct cancer), bladder cancer (advanced urothelial cancer), or any other advanced cancerous tumors?
Do you not currently have a medical condition preventing you from taking medications by mouth?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests KIN-3248, a pill that blocks proteins helping cancer grow, in adults with advanced tumors having FGFR2/FGFR3 gene changes. The drug aims to stop these proteins, potentially slowing or stopping the cancer.
Eligible Conditions
- Liver Cancer
- Solid Tumors
- Bladder Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You have advanced bile duct or bladder cancer, or any other advanced cancer.
Select...
You are able to swallow pills or liquid medication without any medical issues.
Select...
You are not currently pregnant or breastfeeding.
Select...
You must be at least 18 years old or older than the legal age in your area.
Select...
Your tumor has a specific mutation in either the FGFR2 or FGFR3 gene.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Part B - dose expansionExperimental Treatment1 Intervention
Dose expansion evaluating the recommended dose and schedule of KIN-3248 identified from Part A
Group II: Part A - dose escalationExperimental Treatment1 Intervention
Dose escalation of KIN-3248 in patients with solid tumors
Find a Location
Who is running the clinical trial?
Kinnate BiopharmaLead Sponsor
1 Previous Clinical Trials
400 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I'm sorry, it seems that you did not provide a criterion for me to rewrite. Could you please provide me with a criterion?You must be at least 18 years old or older than the legal age in your area.You have advanced bile duct or bladder cancer, or any other advanced cancer.You are able to swallow pills or liquid medication without any medical issues.You are not currently pregnant or breastfeeding.Your tumor has a specific mutation in either the FGFR2 or FGFR3 gene.
Research Study Groups:
This trial has the following groups:- Group 1: Part A - dose escalation
- Group 2: Part B - dose expansion
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Bladder Cancer Patient Testimony for trial: Trial Name: NCT05242822 — Phase 1
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger